Summarized by Masters of Longevity from Longevity Technology.
Longevity investor perspectives on reducing hype and building a neutral center that helps people navigate evidence-based healthspan options.
Key Takeaways
- Investors should demand quantified uncertainty and clear error bars before valuing longevity interventions.
- Building shared discovery labs and only spinning out de-risked programs can reduce early-stage biotech failure costs.
- A neutral longevity center combining a low-cost digital platform with tiered physical services can guide safe, evidence-based healthspan choices.
